Skip to main content
. Author manuscript; available in PMC: 2011 Apr 11.
Published in final edited form as: Semin Breast Dis. 2008 Jun 1;11(2):100–105. doi: 10.1053/j.sembd.2008.03.004

Figure 3.

Figure 3

Monitoring response to treatment with 4 T quantitative breast MRS. This is an update of findings previously reported in Meisamy et al. (11). These data include 28 patients measured with 4 T breast MRI/MRS before the start of chemotherapy, 1 day after the first dose of therapy, and after the complete course of treatment. The tCho measurements are shown for the baseline and day-1 measurements in (a): 75% of the objective responders showed a decrease in tCho at day 1 after therapy, whereas 92% of non-responders showed no change or an increase at the same time point. (b) An example of an objective responder, showing decreased tCho at day 1, and a clear anatomical response by the end of therapy (ACx4). (Figure previously published in NMR Biomed. Haddadin et al 2007).